Showing 1,981 - 2,000 results of 112,045 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((ppm decrease) OR (a decrease)) ))', query time: 1.48s Refine Results
  1. 1981
  2. 1982
  3. 1983
  4. 1984
  5. 1985

    Unusual [3+1] Cycloaddition of a Stable Silylene with a 2,3-Diazabuta-1,3-diene versus [4+1] Cycloaddition toward a Buta-1,3-diene by Yun Xiong (1403545)

    Published 2010
    “…The latter rearranges further to decrease ring strain, affording the corresponding 1-sila-4,5-diazacyclohex-3-ene <b>4</b>. …”
  6. 1986
  7. 1987
  8. 1988

    Microgliosis is decreased in the brains of 5XFAD/<i>LDLR</i>-/- and 5XFAD/<i>ApoE-/-LDLR</i>-/- mice. by Loukia Katsouri (348708)

    Published 2013
    “…Quantitation of Iba1 positive staining in the hippocampi and cortices showing a decrease in the 5XFAD/<i>LDL</i>-/- and 5XFAD/<i>ApoE</i>-/-<i>LDLR</i>-/- mice compared to the control mice. …”
  9. 1989
  10. 1990
  11. 1991

    Astrocytosis is decreased in the brains of 5XFAD/<i>LDLR</i>-/- and 5XFAD/<i>ApoE-/- LDLR</i>-/- mice. by Loukia Katsouri (348708)

    Published 2013
    “…Quantitation of GFAP positive staining in the hippocampi and cortices showing a decrease in the 5XFAD/<i>LDL</i>-/- and 5XFAD/<i>ApoE</i>-/-<i>LDLR</i>-/- mice compared to the control mice. …”
  12. 1992
  13. 1993
  14. 1994

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
  15. 1995
  16. 1996
  17. 1997
  18. 1998

    Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer by Hannah Johnson (1342596)

    Published 2024
    “…A series of compounds were designed utilizing molecular modeling and fragment-based design based upon the known protein phosphatase 2A (PP2A) activators, <b>NSC49L</b> and <b>iHAP1</b>, and evaluated for their ability to inhibit the viability of colorectal cancer (CRC) and folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX)-resistant CRC cells. …”
  19. 1999
  20. 2000